| Brett L Arron, MD | |
|
593 Eddy Street, Davol 129, Providence, RI 02903-4923 | |
| (401) 444-4933 | |
| (401) 444-5090 |
| Full Name | Brett L Arron |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 593 Eddy Street, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205882354 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | ME139000 (Florida) | Secondary |
| 207R00000X | Internal Medicine | 08492 (Rhode Island) | Secondary |
| 207L00000X | Anesthesiology | RI8492 (Rhode Island) | Primary |
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053782466 PECOS PAC ID: 2567455082 Enrollment ID: O20160121000235 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
A research team led by Nagoya University has revealed that cells containing a protein called Meflin have a role in restraining the progression of pancreatic cancer, a type of cancer that is hard to treat with traditional anti-cancer drugs.
For the last year, SEIU officials have been suing 29 local union reformers and whistleblowers who exposed the union's corruption and backroom deals and helped healthcare workers protect their democratic right to join a new union after a hostile takeover.
Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc., Harry S. Palmin.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brett L Arron, MD Po Box 945921, Atlanta, GA 30394-5921 Ph: () - | Brett L Arron, MD 593 Eddy Street, Davol 129, Providence, RI 02903-4923 Ph: (401) 444-4933 |
News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
A research team led by Nagoya University has revealed that cells containing a protein called Meflin have a role in restraining the progression of pancreatic cancer, a type of cancer that is hard to treat with traditional anti-cancer drugs.
For the last year, SEIU officials have been suing 29 local union reformers and whistleblowers who exposed the union's corruption and backroom deals and helped healthcare workers protect their democratic right to join a new union after a hostile takeover.
Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc., Harry S. Palmin.
› Verified 5 days ago
Dr. Keith-austin Scarfo, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 6, Providence, RI 02903 Phone: 401-444-3777 Fax: 401-444-7249 | |
Dr. William Arthur Yelle, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 401-456-2000 | |
Dr. Joshua Kenneth Potvin, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-606-4286 Fax: 401-444-5090 | |
Dr. Henry Huang, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5172 Fax: 401-444-5090 | |
Jonathan D Uri, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Joseph Caiati, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 593 Eddy Street, Davol 129, Providence, RI 02903 Phone: 401-444-4933 Fax: 401-444-5090 | |
Bruce Winter, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 101 Dudley St, Women & Infants Hospital, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7533 |